Literature DB >> 17379960

Long-term follow-up of patients with multiple endocrine neoplasia type 1.

Akihiro Sakurai1, Miyuki Katai, Koh Yamashita, Jun-Ichiro Mori, Yoshimitsu Fukushima, Kiyoshi Hashizume.   

Abstract

Whether early surgical treatment of non-functioning pancreas islet cell tumor (NFPT) provides a favorable quality of life and life expectancy in patients with multiple endocrine neoplasia type 1 (MEN1) remains controversial. We analyzed the long-term clinical courses and surgical outcomes of 14 Japanese patients with MEN1-associated NFPTs. NFPTs smaller than 20 mm in diameter did not show any apparent growth over a long monitoring period. Furthermore, these small NFPTs did not metastasize to regional lymph nodes or the liver. On the other hand, the development of additional NFPTs or metastasis was found in five of six patients with large (35 mm or larger) NFPTs. Among the seven patients who underwent a partial pancreatectomy, six patients developed impaired glucose tolerance or diabetes. The accumulation of more prospective data is needed to clarify the optimal surgical indications for patients with NFPTs, especially among the Japanese population, which has a relatively low insulin secretion potency compared with non-Hispanic white and African-American populations.

Entities:  

Mesh:

Year:  2007        PMID: 17379960     DOI: 10.1507/endocrj.k06-147

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  12 in total

Review 1.  Contemporary management of nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Rebecca M Minter; Diane M Simeone
Journal:  J Gastrointest Surg       Date:  2011-10-19       Impact factor: 3.452

Review 2.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy.

Authors:  Robert T Jensen; Jeffrey A Norton
Journal:  Pancreas       Date:  2017 May/Jun       Impact factor: 3.327

Review 4.  Care for patients with multiple endocrine neoplasia type 1: the current evidence base.

Authors:  C R C Pieterman; M R Vriens; K M A Dreijerink; R B van der Luijt; G D Valk
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

Review 5.  Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

Authors:  S M Sadowski; C R C Pieterman; N D Perrier; F Triponez; G D Valk
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

6.  Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Int J Endocr Oncol       Date:  2016-01-18

Review 7.  Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment.

Authors:  Cynthia Ro; Wanxing Chai; Victoria E Yu; Run Yu
Journal:  Chin J Cancer       Date:  2012-12-14

8.  A case of type 1 multiple endocrine neoplasia with esophageal stricture successfully treated with endoscopic balloon dilation and local steroid injection combined with surgical resection of gastrinomas.

Authors:  Hiroyuki Matsubayashi; Noboru Kawata; Naomi Kakushima; Masaki Tanaka; Kohei Takizawa; Yoshimi Kiyozumi; Yasue Horiuchi; Keiko Sasaki; Teiichi Sugiura; Katsuhiko Uesaka; Hiroyuki Ono
Journal:  BMC Gastroenterol       Date:  2017-03-07       Impact factor: 3.067

Review 9.  Current and emerging therapies for PNETs in patients with or without MEN1.

Authors:  Morten Frost; Kate E Lines; Rajesh V Thakker
Journal:  Nat Rev Endocrinol       Date:  2018-02-16       Impact factor: 43.330

Review 10.  Diagnosing Nonfunctional Pancreatic NETs in MEN1: The Evidence Base.

Authors:  Mark J C van Treijen; Dirk-Jan van Beek; Rachel S van Leeuwaarde; Menno R Vriens; Gerlof D Valk
Journal:  J Endocr Soc       Date:  2018-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.